Adverse events associated with oral small-molecule drugs in the treatment of psoriasis and psoriatic arthritis: a pharmacovigilance study based on the FAERS database

This data is the supplementary data for a manuscript entitled "Adverse events associated with oral small-molecule drugs in the treatment of psoriasis and psoriatic arthritis: a pharmacovigilance study based on the FAERS database. In our study, we revealed the distinct adverse event (AE) profiles of two marketed oral small-molecule drugs, namely apremilast and deucravacitinib.